Patients with metabolic syndrome included to Naoku et al. [215] randomized study, who have been treated with ezetimibe and orlistat or these two drugs combined, showed significant increase in PON1 activity and PON1/HDL-C ratio. Here, PON1 is linked to metabolic syndrome.